ClinicaliQ Trial Snapshot
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — Recruiting • Phase III • Oncology • NCT06615479.
- What is being tested: BMS-986393 (arlo-cel), a novel therapeutic agent, is being compared against standard treatment regimens in patients with relapsed or refractory multiple myeloma who have previously been exposed to lenalidomide.
- Patient eligibility overview: The trial enrolls adult patients with multiple myeloma that has either relapsed (returned after initial treatment) or proven refractory (resistant to prior therapy), with documented prior lenalidomide exposure, representing a heavily pre-treated patient population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Eligibility Snapshot
- * Participants must have relapsed or refractory multiple myeloma (RRMM). * Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide. * Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria. * Participants must have measurable disease during screening. * Participants must have adequate organ function. * Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.